Class I recall for Siemens bacterial infection tests

Siemens Healthcare Diagnostics' Rapid Gram Negative Combo Panels measuring bacteria to determine antibiotic treatment are under a Class I recall from the FDA. The agency said the tests, which are meant to identify certain gram negative bacteria and measure how these bacteria respond to antibiotics to help healthcare providers select the correct treatment for a patient, are inaccurately reporting certain bacteria as sensitive to certain antibiotics when they are in fact resistant. The incorrect test results relate to these antibiotics: Aztreonam, Cefotaxime, Ceftazidime, and Ceftriaxone. The tests were recalled because they can cause ineffective treatment and, in rare instances, may contribute to death. Safety Alert

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.